Escitalopram in major depressive disorder: Clinical benefits and cost effectiveness versus citalopram

International Journal of Psychiatry in Clinical Practice

Volumn 11, Issue 1, 2007, Pages 44-52

  Lançon, Christophe ^a   Verpillat, Patrice ^b   Annemans, Lieven ^c   Despiegel, Nicolas ^d   François, Clément ^d  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b HÔPITAL LOUIS MOURIER   (France)

^c GHENT UNIVERSITY   (Belgium)

^d Lundbeck   (France)

Author keywords

Citalopram; Clinical efficacy; Cost effectiveness; Escitalopram; Major depressive disorder

Indexed keywords

CITALOPRAM; ESCITALOPRAM; SERTRALINE;

AGE DISTRIBUTION; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; OUTPATIENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RATING SCALE; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 33847773145     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500600874527     Document Type: Article

References (38)

1. Sonawalla SB, Fava M. Severe depression: is there a best approach? CNS Drugs 2001;15(10):765-76.
2. Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003;17(5):343-62.
3. Paykel ES, Brugha TF, T. Size and burden of depressive disorders in Europe. European Neuropsychopharmacology 2005;15:411-23.
4. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? Journal of Clinical Psychiatry 2003;64:1465-75.
5. Ferrier IN. Treatment of major depression: is improvement enough? J Clin Psychiatry 1999;60(Suppl 6):10-4.
6. Williams JW, Mulrow CD, Chiquette E, Hitchcock Noel P, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Annals of Internal Medicine 2000;132(9):743-56.
7. Chen F, Larsen MB, Sanchez C, Wiborg O. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. European Neuropsychopharmacology 2005;15:193-8.
8. Svensson S, Mansfield PR. Escitalopram: superior to citalopram or a chiral chimera? Psychotherapy Psychosomatics 2004;73:10-6.
9. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001;50(5):345-50.
10. Hyttel J, Bogeso KP, Perregaard J, Sanchez C. The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 1992;88(2):157-60.
11. Chen F, Larsen MB, Neubauer HA, Sanchez C, Plenge P, Wiborg O. Characterization of an allosteric citalopram-binding site at the serotonin transporter. Journal of Neurochemistry 2005;92:21-8.
12. Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 2004;174(2):163-76.
13. Mork A, Kreilgaard M, Sanchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 2003;45(2):167-73.
14. Sanchez C, Kreilgaard M. R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 2004;77(2):391-8.
15. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63(4):331-6.
16. Lepola UM, Loft H, Reines EH. Escitalopram (10 -20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18(4):211-7.
17. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004;65(1):44-9.
18. Forest Laboratories. Flexible-dose comparison of the safety and efficacy of Lu 26-054 (escitalopram), citalopram, and placebo in the treatment of major depressive disorder. 2005 [cited 29 September 2005]; Available from: www.forestclinicaltrials. com
19. Colonna L, Andersen HF, Reines EH. A randomised, double-blind 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 2005;21(10):1659-68.
20. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20(3):131-7.
21. Auquier P, Robitail S, Llorca P-M, Rive B. Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psychiatry Clin Pract 2003;7:259-68.
22. Colonna L, Reines EH, Andersen HF. Escitalopram is well tolerated and more efficacious than citalopram in long-term treatment of moderately depressed patients. Int J Psychiatry Clin Pract 2002;6(4):243-4.
23. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50(1):57-64.
24. Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol 2004;19(5):305-10.
25. Azorin JM, Llorca PM, Despiegel N, Verpillat P. Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder]. Encephale 2004;30(2):158-66.
26. Llorca PM, Azorin JM, Despiegel NV, P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005;59(3):268-75.
27. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41.
28. Thompson C. Onset of action of antidepressants: results of different analyses. Hum Psychopharmacol 2002;17(Suppl 1):S27-32.
29. Lalit V, Prakash MA, Rajendra PH, Anukant KM, Sunil M, Rajesh N, et al. Escitalopram versus citalopram and sertraline: a double-blind controlled, multi-centric trial in Indian patients with unipolar major depression. Indian Journal of Psychiatry 2004;46(4):333-41.
30. Francois C. Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of budgetary impact. Journal of Drug Assessment 2002;5:221-7.
31. Francois C, Toumi M, Aakhus AM, Hansen K. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur J Health Econ 2003;4(1):12-9.
32. Hemels ME, Kasper S, Walter E, Einarson TR. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Curr Med Res Opin 2004;20(6):869-78.
33. Hemels ME, Kasper S, Walter E, Einarson TR. Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression. Ann Pharmacother 2004;38(6):954-60.
34. Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005;14(4):339-47.
35. Demyttenaere K, Hemels ME, Hudry J, Annemans L. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther 2005;27(1):2111-24.
36. Wade AG, Toumi I, Hemels ME. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin 2005;21(4):631-41.
37. Wade AG, Toumi I, Hemels ME. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin Ther 2005;27(4):486-96.
38. Fantino B, Moore N, Verdoux H, Auray J-P. Cost-effectiveness of escitalopram versus citalopram in major depressive disorder. International Clinical Psychopharmacology 2005;Submitted.